Clinical Trial Update: CD19-targeting 3rd Generation CAR T Cells for Refractory B Cell Malignancy - a Phase I/IIa Trial. [Phase 1, Phase 2]

View source ↗

Summary

A Phase I/IIa trial evaluating CD19-targeting third-generation CAR T cells for refractory B-cell malignancies has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Leukemia
• B-cell Lymphoma

Drugs mentioned

• CD19-targeting 3rd Generation CAR T Cells (Third-generation anti-CD19 CAR T-cell therapy)

Snippet

Sponsor: Uppsala University | Conditions: B Cell Lymphoma, B Cell Leukemia | Phase 1, Phase 2 | Status: COMPLETED